Study of Doxorubicin and S9788 in Advanced Cancer
Author Information
Author(s): CJA Punt, EE Voest, E Tueni, AT Van Oosterom, A Back, PHM De Mulder, B Hecquet, C Lucas, B Gerard, H Bleiberg
Primary Institution: University Hospital Nijmegen, The Netherlands
Hypothesis
Can S9788 effectively reverse multidrug resistance in patients with advanced colorectal and renal cell cancer when combined with doxorubicin?
Conclusion
The combination of S9788 and doxorubicin achieved relevant concentrations of S9788 but resulted in significant cardiac arrhythmias, leading to the study's termination.
Supporting Evidence
- One patient achieved a partial response after previously progressing on doxorubicin alone.
- Significant increase in WHO grade 3-4 granulocytopenia was observed with the combination treatment.
- Cardiac arrhythmias were noted in patients receiving the combination treatment.
Takeaway
Doctors tested a new drug called S9788 with another drug, doxorubicin, to help treat cancer, but they found it caused heart problems, so they stopped the study.
Methodology
Patients with advanced colorectal or renal cell cancer were treated with doxorubicin alone or in combination with S9788, and their responses and side effects were monitored.
Potential Biases
Potential bias due to non-randomized treatment assignment and small sample size.
Limitations
The study was terminated early due to safety concerns regarding cardiac arrhythmias.
Participant Demographics
Median age was 61 years, with 27 patients having colorectal cancer and 11 with renal cell cancer.
Statistical Information
P-Value
0.001
Confidence Interval
95% CI 1.9-17% for colorectal cancer response rate
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website